PBL awared further US patents on short RNAi molecules
These two new patents granted add to the strength and breadth of PBL’s RNAi patent portfolio. The patent family now comprises a total of 9 granted US patents, which cover a wide area of RNAi applications from detection of gene silencing, to methods to silence genes, and compositions and cells containing and producing RNAi molecules.
On 24 June 2014 US Patent No. 8,759,102 was granted with claims to cells comprising synthetic DNA constructs that express RNAi molecules to silence target RNA in these cells.
Dr Jan Chojecki, Managing Director of PBL adds “We are very pleased, that the USPTO has over the past two and a half years recognised Professor Sir David Baulcombe’s and Dr Andrew Hamilton’s contribution to the field of RNAi and PBL now holds a substantial patent portfolio in the area, covering many aspects and applications of RNAi. Several potential products are currently in clinical trials and product development with our partners. We are looking forward to the market introduction of RNAi based therapeutics and plant health agents which will demonstrate the unique ability of RNAi to improve medicine and agriculture. Furthermore we anticipate partnering with more companies interested in the diverse applications of RNAi.”
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.